LXRX - LEXICON PHARMACEUTICALS, INC.
IEX Last Trade
0.7669
-0.002 -0.287%
Share volume: 56,208
Last Updated: Fri 27 Dec 2024 08:30:10 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.77
0.00
-0.29%
Fundamental analysis
13%
Profitability
0%
Dept financing
11%
Liquidity
75%
Performance
10%
Performance
5 Days
-5.10%
1 Month
-2.50%
3 Months
-50.95%
6 Months
-54.90%
1 Year
-46.25%
2 Year
-57.11%
Key data
Stock price
$0.77
DAY RANGE
$0.74 - $0.81
52 WEEK RANGE
$0.70 - $3.73
52 WEEK CHANGE
-$48.71
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Lonnel Coats
Region: US
Website: lexpharma.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lexpharma.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Lexicon Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the. treatment of neuropathic pain.
Recent news